A Phase 1 Study of Cabozantinib in Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors: Trial ADVL1211, A Report from the Children’s Oncology Group

BACKGROUND: We conducted a phase 1 trial to determine the maximum tolerated dose (MTD), toxicity profile, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of cabozantinib in children with refractory or relapsed solid tumors. METHODS: Patients received cabozantinib tablets on a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pediatr Blood Cancer
Hlavní autoři: Chuk, Meredith K., Widemann, Brigitte C., Minard, Charles G., Liu, Xiaowei, Kim, AeRang, Bernhardt, M. Brooke, Kudgus, Rachel A., Reid, Joel M., Voss, Stephan D., Blaney, Susan, Fox, Elizabeth, Weigel, Brenda J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6082380/
https://ncbi.nlm.nih.gov/pubmed/29693796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.27077
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky